Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
December 2010

Asenapine: More Data
Olanzapine (Zyprexa) may be better tolerated and more efficacious for patients with bipolar I disorder than asenapine (Saphris).

Sibutramine (Meridia and others): Risks versus Benefits
After a large trial found a higher frequency of adverse cardiovascular events in sibutramine- versus placebo-treated patients, this "diet pill" was withdrawn from the US market.

Antidepressants and Weight Gain
While some antidepressants have no significant effect on body weight, many may cause weight gain or loss during short- or long-term treatment.

In Brief
Psychiatric Disorders Associated with Suicide Attempts in Prisoners; Buprenorphine Implants for Opioid Dependence

Bupropion for Smoking Cessation in People with Schizophrenia
In smokers with schizophrenia, bupropion (Wellbutrin, Zyban, and others) increases the odds of abstinence.

2010: Close and Save
Dr. Gelenberg's end-of-year editorial and holiday message.

INDEX
2010 Index

Asenapine: More Data

December 2010

Last January, we featured asenapine (Saphris), a new second-generation antipsychotic (BTP 2010;33:1-2). Approved in August 2009 by the US Food and Drug Administration, asenapine is labeled for the acute treatment of schizophrenia and for manic and mixed episodes in adults with bipolar I disorder.…

To view the rest of this article, please: